Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.70 |
| ▸ | GNAI3 | P08754 | 6/20 | 0.61 |
| ▸ | GNAO1 | P09471 | 6/20 | 0.61 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.61 |
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | GUSB | P08236 | 2/20 | 0.48 |
| ▸ | EBP | Q15125 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28154297 | 1.00 | HRH3 (0.70) | HRH3GNAI3GNAO1GNAI1LTA4H | |
| SCHEMBL1187251 | 1.00 | HRH3 (0.70) | HRH3GNAI3GNAO1GNAI1LTA4H | |
| SCHEMBL1261593 | 1.00 | HRH3 (0.70) | HRH3GNAI3GNAO1GNAI1LTA4H | |
| SCHEMBL1261675 | 1.00 | HRH3 (0.70) | HRH3GNAI3GNAO1GNAI1LTA4H | |
| SCHEMBL898870 | 1.00 | HRH3 (0.70) | HRH3GNAI3GNAO1GNAI1LTA4H | |
| SCHEMBL1261708 | 1.00 | HRH3 (0.70) | HRH3GNAI3GNAO1GNAI1LTA4H | |
| SCHEMBL6114812 | 1.00 | HRH3 (0.70) | HRH3GNAI3GNAO1GNAI1LTA4H | |
| SCHEMBL1564984 | 1.00 | HRH3 (0.70) | HRH3GNAI3GNAO1GNAI1LTA4H | |
| SCHEMBL1262700 | 1.00 | HRH3 (0.70) | HRH3GNAI3GNAO1GNAI1LTA4H | |
| SCHEMBL28106520 | 1.00 | HRH3 (0.70) | HRH3GNAI3GNAO1GNAI1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076760-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | WAKAMOTO PHARMACEUTICAL CO., LTD (JP) | 2008-03-27 | — | — | US | disclosed |
| EP-1820799-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | Wakamoto Pharmaceutical Co., Ltd. (JP) | 2007-08-22 | — | — | EP | disclosed |
| US-4727073-A | CEREBOVASCULAR DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-02-23 | — | — | US | disclosed |
| US-4698340-A | TREATMENT OF CEREBROVASCULAR DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1987-10-06 | — | — | US | disclosed |
| EP-0177287-A2 | Pyrimidine derivatives, processes for preparation thereof and composition of the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076760-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | GABRA5, GABRA1, GABRB1 | HRH3 734/4885GNAI3 1131/4885GNAO1 1472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.